: This edition introduced over 130 new monographs , including critical treatments for cystic fibrosis (Lumacaftor) and narcolepsy (Pitolisant).
The is a globally recognised, two-volume pharmaceutical encyclopaedia providing evidence-based information on drugs and medicines used worldwide. It is widely considered the "gold standard" for pharmacists and clinicians due to its comprehensive, unbiased monographs that cover licensed drugs from 43 countries and regions. Review of Key Features : This edition introduced over 130 new monographs
. This is the most reliable way to access the 40th and current 41st editions, featuring regular updates on new monographs and treatment reviews. Institutional Access : This edition introduced over 130 new monographs